GlassScriptPhysician profile
Andrew N Eskander
NPI 1669907275
$29,631.80
in general payments reported to CMS, 2019-2025
31 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,556 · 2020: $414 · 2021: $525 · 2022: $767 · 2023: $22K · 2024: $1,022 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $2,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,000.00 |
| Food and Beverage | $2,369.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amnio Technology, LLC | $21,000.00 | 2023 | |
| Stryker Corporation | $2,542.17 | 2019-2025 | Prophecy, Augment Injectable, Citrefix |
| Paragon 28, INC. | $1,042.31 | 2019-2025 | Precision Mis Bunion |
| Amniox Medical, INC. | $728.41 | 2019-2020 | |
| Koya Medical, INC. | $525.02 | 2024 | Dayspring, Koya Medical |
| Horizon Therapeutics Plc | $513.69 | 2019-2023 | Krystexxa |
| Cardiovascular Systems INC. | $374.89 | 2019-2022 | |
| Inari Medical, INC. | $368.42 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Integra Lifesciences Corporation | $305.49 | 2019-2021 | |
| Biotissue Holdings INC. | $277.95 | 2019 | |
| Amgen INC. | $251.27 | 2024-2025 | Krystexxa |
| Depuy Synthes Sales INC. | $250.66 | 2019-2024 | |
| Treace Medical Concepts, INC. | $246.90 | 2020-2022 | |
| Abbott Laboratories | $149.78 | 2023 | Eterna |
| Nevro Corp. | $135.40 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $130.77 | 2022-2025 | Nuzyra |
| Lilly USA, LLC | $121.90 | 2022 | |
| Merck Sharp & Dohme LLC | $118.93 | 2019-2024 | Bridion |
| Melinta Therapeutics, LLC | $109.93 | 2019 | |
| Organogenesis INC. | $97.21 | 2022-2025 | Puraply, Apligraf |
| Smith+Nephew, INC. | $88.72 | 2022 | |
| Zimmer Biomet Holdings, INC. | $46.07 | 2019 | |
| Lifenet Health | $35.43 | 2023 | |
| Trevena, INC. | $33.35 | 2021 | |
| Kerecis Limited | $30.60 | 2021 | |
| Davol INC. | $23.40 | 2025 | Arista |
| Scilex Pharmaceuticals INC. | $20.50 | 2024 | |
| Bioventus LLC | $19.60 | 2021 | |
| Fidia Pharma USA INC. | $19.50 | 2020 | |
| Tactile Systems Technology INC | $12.28 | 2019 | |
| Globus Medical, INC. | $11.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Eskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.